A.W.S. Ritchie
MRC Clinical Trials Unit at UCL(GB)University College London(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial(2015)1,944 cited
- → Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy(2017)1,740 cited
- → Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial(2018)1,235 cited
- → Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)(2014)433 cited
- → Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial(2019)395 cited
- → Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol